# Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer

> **NCT00003009** · PHASE1 · TERMINATED · sponsor: **University of Southern California** · enrollment: 16 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00003009
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-02
- **Primary completion:** 2000-08
- **Final completion:** 2000-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Insufficient Accrual
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003009, "Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*